Skip to main content
Article
Comparison of Weekly Versus Triweekly Cisplatin Delivered Concurrently with Radiation Therapy in Patients with Locally Advanced Nasopharyngeal Cancer: A Multicenter Randomized Phase II Trial (KCSG-HN10-02)
Radiotherapy & Oncology (2016)
  • Ji Yun Lee, Sungkyunkwan University School of Medicine
  • Jong-Mu Sun, Sungkyunkwan University School of Medicine
  • Dong Ryul Oh, Sungkyunkwan University School of Medicine
  • Sung Hee Lim, Sungkyunkwan University School of Medicine
  • Juna Goo, Sungkyunkwan University School of Medicine
  • Se-Hoon Lee, Sungkyunkwan University School of Medicine
Abstract
Purpose

Triweekly delivery of cisplatin concurrent with a course of radiation therapy (RT) has been the standard regimen for treatment of locally advanced nasopharyngeal carcinoma (NPC) despite a high level of concern regarding treatment-related complications. We conducted a randomized phase II study to compare weekly and triweekly cisplatin delivery during RT with respect to efficacy and toxicity profiles.

Material and methods

Patients with locally advanced NPC (stage II–IVb) were randomly assigned to a regimen of either seven doses of cisplatin (40 mg/m2) given once a week or three doses of cisplatin (100 mg/m2) given every 3 weeks concurrently during RT.

Results

Of 109 eligible patients, 53 were assigned to the weekly regimen and 56 to the triweekly regimen. The two groups were comparable with respect to demographic and clinical characteristics. There were no significant differences in mean RT dose (68.3 Gy vs. 67.3 Gy, p= 0.559) and mean cisplatin dose (248.9 mg/m2 vs. 256.6 mg/m2p= 0.433) between the two regimens. The primary endpoint was 3-year progression-free survival, which was not different between the regimens (64.9% vs. 63.8%, p= 0.074). Overall, the occurrence of grade 3–4 toxicities was similar between the two arms (47.2% vs. 39.3%, p= 0.443). Quality of life (QoL) related to functional outcomes 3 weeks after treatment completion was better for the weekly regimen.

Conclusions

Although no definitive conclusions can be made, a once-weekly cisplatin regimen appears to be associated with improved QoL and is not inferior to the standard triweekly regimen with respect to efficacy and toxicity profiles.
Keywords
  • concurrent chemoradiation therapy,
  • nasopharyngeal cancer,
  • efficacy,
  • toxicity,
  • quality of life
Publication Date
February, 2016
DOI
https://doi.org/10.1016/j.radonc.2015.11.030
Publisher Statement
For a complete list of authors see the article.
Citation Information
Lee, Ji-Yun; Sun, Jong-Mu; Oh, Dong Ryul; Lim, Sung Hee; Goo, Juna; Lee, Se-Hoon; . . . and Ahn, Myung-Ju. (2015). "Comparison of Weekly Versus Triweekly Cisplatin Delivered Concurrently with Radiation Therapy in Patients with Locally Advanced Nasopharyngeal Cancer: A Multicenter Randomized Phase II Trial (KCSG-HN10-02)". Radiotherapy & Oncology, 118(2), 244.250. https://doi.org/10.1016/j.radonc.2015.11.030